Century Therapeutics (IPSC) Cash from Operations (2020 - 2026)

Century Therapeutics (IPSC) has 7 years of Cash from Operations data on file, last reported at 25262000.0 in Q1 2026.

• On a quarterly basis, Cash from Operations rose 27.04% year-over-year to 25262000.0 in Q1 2026; TTM through Mar 2026 was 94539000.0, a 17.44% increase from a year earlier, with the FY2025 full-year figure at 103900000.0, up 5.66% from the prior year.
• Cash from Operations for Q1 2026 stood at 25262000.0, down from 16101000.0 in the prior quarter.
• Over the last five years, Cash from Operations for IPSC reached as high as 86753000.0 in Q1 2022 and fell as low as 34623000.0 in Q1 2025.
• Historically, Cash from Operations has averaged 18446647.06 across 5 years, with a median of 25556000.0 in 2022.
• Across the five-year window, Cash from Operations soared 491.15% in 2022 and tumbled 133.68% in 2023, its largest moves.
• Year by year, Cash from Operations stood at 22907000.0 in 2022, then retreated by 14.51% to 26230000.0 in 2023, then increased by 7.65% to 24223000.0 in 2024, then surged by 33.53% to 16101000.0 in 2025, then sank by 56.9% to 25262000.0 in 2026.
• Per Business Quant data, the three most recent Cash from Operations figures were 25262000.0 in Q1 2026, 16101000.0 in Q4 2025, and 25584000.0 in Q3 2025.